Teva, Alvotech and FDA
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...
Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback